LLB LLM - Theratechnologies General Secretary
| THTX Stock | USD 1.20 0.01 0.83% |
Executive
LLB LLM is General Secretary of Theratechnologies
| Age | 56 |
| Address | 2015 Peel Street, Montreal, QC, Canada, H3A 1T8 |
| Phone | 514 336 7800 |
| Web | https://www.theratech.com |
Theratechnologies Management Efficiency
The company has return on total asset (ROA) of 0.1176 % which means that it generated a profit of $0.1176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.1686) %, meaning that it created substantial loss on money invested by shareholders. Theratechnologies' management efficiency ratios could be used to measure how well Theratechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.39 in 2024, whereas Return On Tangible Assets are likely to drop (0.44) in 2024. At this time, Theratechnologies' Non Current Assets Total are fairly stable compared to the past year. Other Assets is likely to rise to about 2.2 M in 2024, whereas Total Assets are likely to drop slightly above 65.2 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Richard MD | Lyra Therapeutics | 61 | |
| Catherine Thorpe | Applied Therapeutics | 60 | |
| April Dovholuk | Centessa Pharmaceuticals PLC | N/A | |
| Christian Mirescu | Vigil Neuroscience | N/A | |
| Deborah JD | Nuvalent | 48 | |
| JD Esq | Centessa Pharmaceuticals PLC | N/A | |
| John Moore | Edgewise Therapeutics | 60 | |
| Marc MD | Edgewise Therapeutics | 67 | |
| Laurent Lannoo | Genfit | 53 | |
| MSc MD | Centessa Pharmaceuticals PLC | 66 | |
| Stefan Abele | Pharvaris BV | 54 | |
| Gerhard Frey | Bioatla | N/A | |
| Eugene Scavola | Verrica Pharmaceuticals | N/A | |
| Kristina Meyer | Inventiva Sa | N/A | |
| John Soglia | Nuvalent | N/A | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| John Brozek | Genfit | 47 | |
| Karen MBA | Vincerx Pharma | N/A | |
| David Gray | Vigil Neuroscience | 49 | |
| Joe Bonaccorso | Verrica Pharmaceuticals | 60 | |
| Cara Miller | Tarsus Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -11.17 | ||||
| Return On Asset | 0.12 |
Theratechnologies Leadership Team
Elected by the shareholders, the Theratechnologies' board of directors comprises two types of representatives: Theratechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theratechnologies. The board's role is to monitor Theratechnologies' management team and ensure that shareholders' interests are well served. Theratechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theratechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| LLB BA, VP Affairs | ||
| H MSc, Vice Resources | ||
| LLB LLM, General Secretary | ||
| Elif McDonald, Director Relations | ||
| Paul Lvesque, CEO President | ||
| MBA MBA, Senior CFO | ||
| Christian Marsolais, Senior Officer | ||
| John Leasure, Global Officer |
Theratechnologies Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theratechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.17 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 73.9 M | ||||
| Shares Outstanding | 45.98 M | ||||
| Shares Owned By Insiders | 1.22 % | ||||
| Shares Owned By Institutions | 51.56 % | ||||
| Number Of Shares Shorted | 43.03 K | ||||
| Price To Book | 20.13 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Theratechnologies Stock Analysis
When running Theratechnologies' price analysis, check to measure Theratechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theratechnologies is operating at the current time. Most of Theratechnologies' value examination focuses on studying past and present price action to predict the probability of Theratechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theratechnologies' price. Additionally, you may evaluate how the addition of Theratechnologies to your portfolios can decrease your overall portfolio volatility.